About: Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites
Creator	Hong, Zhongsi Shan, Hong Zhang, Hong Yan, Yan Zhang, Liping Zhang, Changsheng Kang, S Chen, Qiuyue Chen, Shoudeng Chen, Xiaoxue He, Suhua Huang, Zhaoxia Kang, Sisi Yang, Mei Zhou, Zhechong Zhou, Ziliang
source	Elsevier; Medline; PMC
abstract	The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 Å crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the β-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2.
has issue date	2020-04-20(xsd:dateTime)
bibo:doi	10.1016/j.apsb.2020.04.009
bibo:pmid	32363136
has license	no-cc
sha1sum (hex)	570cfde13f4d44ac12a1341b942f54890889f3a3
schema:url	https://doi.org/10.1016/j.apsb.2020.04.009
resource representing a document's title	Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites
has PubMed Central identifier	PMC7194921
has PubMed identifier	32363136
schema:publication	Acta Pharm Sin B
resource representing a document's body	covid:570cfde13f4d44ac12a1341b942f54890889f3a3#body_text
is schema:about of	named entity 'nucleocapsid' named entity 'potential' named entity 'nucleocapsid' named entity 'protein' named entity 'type' named entity 'Further' named entity 'protein' named entity 'Viral' named entity 'targeting' named entity 'drug targeting' named entity 'binding domain' named entity 'provide' named entity 'N-terminal domain' named entity 'https' named entity 'virus' named entity 'structural' named entity 'domains' named entity 'serving' named entity 'mild' named entity 'However' named entity 'specific' named entity 'human' named entity 'worldwide' named entity 'N-terminal domain' named entity 'potential' named entity 'crystal structure' named entity 'antiviral drugs' named entity 'nucleocapsid protein' named entity 'SARS-CoV-2' named entity 'nucleocapsid protein' named entity 'SARS-CoV-2' named entity 'viral life cycle' named entity 'antiviral agents' named entity 'nucleocapsid protein' named entity 'electrostatic potential' named entity 'drug targeting' named entity 'SARS-CoV-2' named entity 'N-terminal' named entity 'RNA binding' named entity 'Crystal structure' named entity 'RNA binding' named entity 'drug targeting' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'nucleocapsid' named entity 'nitrogenous base' named entity 'column chromatography' named entity 'protein' named entity 'HCoV-OC43' named entity 'SARS-CoV-2' named entity 'nucleotide' named entity 'helical' named entity 'transcription' named entity 'HCoV-OC43' named entity 'positively charged' named entity 'molecular replacement' named entity 'World Health Organization' named entity 'N-terminal domain' named entity 'R-factor' named entity 'SARS-CoV-2' named entity 'Nucleocapsid' named entity 'Nucleocapsid' named entity 'N-terminal tail' named entity 'SARS-CoV-2' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software